6-Feb-2026
TipRanks (Fri, 6-Feb 6:30 AM ET)
Best-in-Class Real-World Data Support Early Amtagvi Treatment in Advanced Melanoma
Globe Newswire (Thu, 5-Feb 5:15 PM ET)
Barclays Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)
TipRanks (Wed, 4-Feb 4:16 AM ET)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire (Fri, 16-Jan 5:15 PM ET)
Globe Newswire (Mon, 12-Jan 3:31 PM ET)
Biotech Valuations Rise as New Clinical Platforms Show Progress
Globe Newswire (Mon, 24-Nov 8:30 AM ET)
Market Chameleon (Thu, 6-Nov 5:31 AM ET)
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Iovance Biotherapeutics trades on the NASDAQ stock market under the symbol IOVA.
As of February 6, 2026, IOVA stock price climbed to $2.53 with 6,561,118 million shares trading.
IOVA has a beta of 1.66, meaning it tends to be more sensitive to market movements. IOVA has a correlation of 0.06 to the broad based SPY ETF.
IOVA has a market cap of $915.49 million. This is considered a Small Cap stock.
Last quarter Iovance Biotherapeutics reported $67 million in Revenue and -$.25 earnings per share. This fell short of revenue expectation by $-4 million and exceeded earnings estimates by $.02.
In the last 3 years, IOVA traded as high as $18.33 and as low as $1.64.
The top ETF exchange traded funds that IOVA belongs to (by Net Assets): VTI, XBI, IWM, VB, VXF.
IOVA has underperformed the market in the last year with a price return of -57.0% while the SPY ETF gained +15.1%. However, in the short term, IOVA had mixed performance relative to the market. It has outperformed in the last 3 months, returning +9.5% vs +3.3% return in SPY. But in the last 2 weeks, IOVA shares have been beat by the market, returning -4.2% compared to an SPY return of +0.2%.
IOVA support price is $2.22 and resistance is $2.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IOVA shares will trade within this expected range on the day.